Triptolide (Synonyms: 雷公藤甲素; PG490)

目录号: HY-32735 纯度: 99.86%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Triptolide是从雷公藤根中提取的二萜类三环氧化物，具有免疫抑制，抗炎，抗增殖和抗肿瘤作用。雷公藤内酯是 NF-κB 活化的抑制剂。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Triptolide Chemical Structure

CAS No. : 38748-32-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥1150	In-stock
1 mg	￥520	In-stock
2 mg	￥910	In-stock
5 mg	￥1450	In-stock
10 mg	￥2250	In-stock
25 mg	￥4500	In-stock
50 mg		询价
100 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Triptolide:

Triptolide-d₃ 询价
Triptolide (Standard) 询价

MCE 顾客使用本产品发表的 43 篇科研文献

: Triptolide purchased from MCE. Usage Cited in: Int J Mol Sci. 2016 Dec 19;17(12). pii: E2139. [Abstract]; To explore the cellular mechanisms for the suppression of CNE cells by TPL and IR, the expression of p65, phosph-p65, Bcl-2, and Bax in CNE cells are examined by Western blot, with β-actin as protein loading control. Western blot assay for Bax, Bcl-2, phosph-p65, and p65 expression in vitro with combined treatment with TPL and IR.

Triptolide 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 NF-κB 亚型特异性产品:

查看所有亚型

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor^[1]^[2]^[3]^[4]^[5]^[6].

IC₅₀ & Target^[1]^[2]

HSP90

MDM-2/p53

47-73 nM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
786-0	IC₅₀	0.022 μM Compound: 1	Cytotoxicity against human 786-O cells after 72 hrs by MTT assay Cytotoxicity against human 786-O cells after 72 hrs by MTT assay	[PMID: 19637874]
A549	IC₅₀	0.0175 μM Compound: Triptolide	Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
A549	IC₅₀	0.059 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19637874]
A549	IC₅₀	14 nM Compound: 19	Antagonist activity at human PAR2 expressed in human A549 cells assessed as inhibition of 2f-LIGRLO-NH2-induced NFkappaB activation by luciferase reporter gene assay Antagonist activity at human PAR2 expressed in human A549 cells assessed as inhibition of 2f-LIGRLO-NH2-induced NFkappaB activation by luciferase reporter gene assay	[PMID: 23895492]
A549	IC₅₀	23 nM Compound: 19	Antagonist activity at human PAR2 expressed in human A549 cells coexpressing TACR1 assessed as inhibition of substance P-induced IL-8 production by ELISA Antagonist activity at human PAR2 expressed in human A549 cells coexpressing TACR1 assessed as inhibition of substance P-induced IL-8 production by ELISA	[PMID: 23895492]
B16-F10	IC₅₀	0.005 μM Compound: 1	Antiproliferative activity against human B16-F10 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human B16-F10 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 32028140]
Bel-7402	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 19637874]
BGC-823	IC₅₀	0.002 μM Compound: 1	Antiproliferative activity against human BGC-823 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human BGC-823 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 32028140]
DU-145	IC₅₀	0.024 μM Compound: 1	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 19637874]
HaCaT	IC₅₀	0.027 μM Compound: TPL	Cytotoxicity against human HaCaT cells incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
HCT-116	IC₅₀	0.003 μM Compound: 1	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 32028140]
HCT-116	IC₅₀	0.01 μM Compound: 1	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 19637874]
HCT-116	IC₅₀	0.046 μM Compound: TPL	Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
HCT-15	IC₅₀	0.029 μM Compound: 1	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 19637874]
HeLa	IC₅₀	0.043 μM Compound: TP	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
HeLa	IC₅₀	0.047 μM Compound: 1	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19637874]
Hepatocyte	IC₅₀	37.7 nM Compound: TP	Cytotoxicity against primary hepatocytes (unknown origin) after 48 hrs by XTT assay Cytotoxicity against primary hepatocytes (unknown origin) after 48 hrs by XTT assay	[PMID: 30613335]
HepG2	IC₅₀	0.014 μM Compound: 1	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 32028140]
HepG2	IC₅₀	0.033 μM Compound: TP	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
HepG2	IC₅₀	0.468 μM Compound: Triptolide	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay	[PMID: 35476958]
HepG2	IC₅₀	43.3 nM Compound: TP	Cytotoxicity against human HepG2 cells after 48 hrs by XTT assay Cytotoxicity against human HepG2 cells after 48 hrs by XTT assay	[PMID: 30613335]
HT-29	IC₅₀	0.047 μM Compound: TPL	Cytotoxicity against human HT-29 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HT-29 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
HUVEC	IC₅₀	0.044 μM Compound: TPL	Cytotoxicity against HUVEC incubated for 72 hrs by MTT assay Cytotoxicity against HUVEC incubated for 72 hrs by MTT assay	[PMID: 35617856]
K562	IC₅₀	0.05 μM Compound: 1	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19637874]
KB	IC₅₀	0.043 μM Compound: 1	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 19637874]
KBM5	IC₅₀	10.3 nM Compound: 1	Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTS assay Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTS assay	[PMID: 20149665]
KBM5	IC₅₀	8.3 nM Compound: 1	Cytotoxicity against imatinib-resistant human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTS assay Cytotoxicity against imatinib-resistant human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTS assay	[PMID: 20149665]
L02	IC₅₀	0.016 μM Compound: TPL	Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
L02	IC₅₀	0.021 μM Compound: TP	Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
LNCaP	IC₅₀	9.7 nM Compound: 1	Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35247754]
MCF7	IC₅₀	0.019 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19637874]
MCF7	IC₅₀	0.022 μM Compound: TP	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
MDA-MB-231	IC₅₀	0.024 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 19637874]
MDA-MB-231	IC₅₀	0.051 μM Compound: TPL	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
MDA-MB-468	IC₅₀	0.01 μM Compound: 1	Cytotoxicity against human MDA-MB-468 cells by SRB assay Cytotoxicity against human MDA-MB-468 cells by SRB assay	[PMID: 19637874]
MEF	IC₅₀	9200 nM Compound: 1	Cytotoxicity against MEF after 72 hrs by MTS assay Cytotoxicity against MEF after 72 hrs by MTS assay	[PMID: 20149665]
MKN-28	IC₅₀	0.2 μM Compound: 1	Cytotoxicity against human MKN28 cells after 72 hrs by MTT assay Cytotoxicity against human MKN28 cells after 72 hrs by MTT assay	[PMID: 19637874]
MOLT-4	IC₅₀	0.017 μM Compound: 1	Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 19637874]
NCI-H1299	IC₅₀	0.049 μM Compound: TP	Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
NCI-H1650	IC₅₀	0.015 μM Compound: 1	Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 32028140]
NCI-H1975	IC₅₀	0.002 μM Compound: TPL	Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
NCI-H1975	IC₅₀	0.019 μM Compound: TP	Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
NCI-H460	IC₅₀	0.014 μM Compound: TPL	Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
PANC-1	IC₅₀	0.056 μM Compound: TP	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
PANC-1	IC₅₀	0.2 μM Compound: 8; TPL	Cytotoxicity against human Panc-1 cells incubated for 48 hrs by CCK8 assay Cytotoxicity against human Panc-1 cells incubated for 48 hrs by CCK8 assay	[PMID: 33289552]
PC-3	IC₅₀	0.0183 μM Compound: Triptolide	Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
PC-3	IC₅₀	0.02 μM Compound: 1	Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay	[PMID: 20833543]
PC-3	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human PC3 cells by SRB assay Cytotoxicity against human PC3 cells by SRB assay	[PMID: 19637874]
PC-3	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation by sulforhodamine B assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation by sulforhodamine B assay	[PMID: 25467158]
PC-3	IC₅₀	0.021 μM Compound: TP	Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
PC-3	IC₅₀	0.043 μM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 19637874]
PC-3	IC₅₀	20 nM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay	[PMID: 24378709]
PC-3	IC₅₀	20.3 nM Compound: 1	Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35247754]
RAW264.7	IC₅₀	0.014 μM Compound: 1	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 32028140]
RAW264.7	IC₅₀	0.023 μM Compound: 1	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 incubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 32028140]
SGC-7901	IC₅₀	0.015 μM Compound: 1	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 19637874]
SJRH30	IC₅₀	0.014 μM Compound: 1	Cytotoxicity against human Rh30 cells after 72 hrs by MTT assay Cytotoxicity against human Rh30 cells after 72 hrs by MTT assay	[PMID: 19637874]
SK-OV-3	IC₅₀	0.006 μM Compound: 1	Antiproliferative activity against human SKOV3 cells after 72 hrs by SRB assay Antiproliferative activity against human SKOV3 cells after 72 hrs by SRB assay	[PMID: 20833543]
SK-OV-3	IC₅₀	0.0072 μM Compound: Triptolide	Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
SK-OV-3	IC₅₀	0.009 μM Compound: 1	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 19637874]
SK-OV-3	IC₅₀	0.01 μM Compound: 1	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 19637874]
SK-OV-3	IC₅₀	6 nM Compound: 1	Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay	[PMID: 24378709]
SMMC-7721	IC₅₀	0.018 μM Compound: 1	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 19637874]
SW 1116	IC₅₀	0.052 μM Compound: 1	Cytotoxicity against human SW1116 cells after 72 hrs by MTT assay Cytotoxicity against human SW1116 cells after 72 hrs by MTT assay	[PMID: 19637874]
SW480	IC₅₀	50 nM Compound: 77	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 33445154]
SW-620	IC₅₀	0.163 μM Compound: TPL	Cytotoxicity against human SW-620 cells incubated for 72 hrs by MTT assay Cytotoxicity against human SW-620 cells incubated for 72 hrs by MTT assay	[PMID: 35617856]
U-251	IC₅₀	0.033 μM Compound: 1	Cytotoxicity against human U251 cells assessed as inhibition of cell proliferation by sulforhodamine B assay Cytotoxicity against human U251 cells assessed as inhibition of cell proliferation by sulforhodamine B assay	[PMID: 25467158]
U-251	IC₅₀	0.049 μM Compound: 1	Cytotoxicity against human U251 cells after 72 hrs by MTT assay Cytotoxicity against human U251 cells after 72 hrs by MTT assay	[PMID: 19637874]

体外研究
(In Vitro)

Triptolide 在培养的和原发性慢性淋巴细胞白血病 (CLL) B 细胞中诱导细胞凋亡。用 Triptolide 处理 CD19⁺ B 细胞，诱导培养的和原代 CLL 细胞凋亡的剂量依赖性增加。Triptolide 对高风险 (n=5) 和低风险 CLL (n=12) B 细胞 (10-50 nM 范围) 具有选择性毒性，同时在很大程度上保留正常 B 细胞 (n=5)。与抑制热休克诱导的 HSP 转录一致，Triptolide 处理可减弱热休克诱导的 HSP 表达^[1]。
Triptolide 是一种源自中国植物雷公藤的天然产物，据报道在多种癌症中表现出抗肿瘤作用。Triptolide 以剂量依赖性方式抑制 MDM2 表达，即使在 20-100 nM 的低浓度下，在急性淋巴细胞白血病 (ALL) 细胞中也是如此。Triptolide 在所有 8 种具有天然 MDM2 过表达的细胞系中表现出强烈的细胞毒活性，IC₅₀ 值范围为 47 到 73 nM。雷公藤甲素对表达极低水平 MDM2 的 EU-4 细胞的细胞毒性作用要小得多，而当 MDM2 稳定转染时，雷公藤甲素能有效杀死这些细胞 (IC₅₀ 值：725 nM 对 88 nM)^[2]。
分化的 PC12 细胞与不同浓度的 Triptolide (0.01、0.1 和1 nM) 在10 μM Aβ_25-35 存在下孵育 24 小时，MTT 法检测雷公藤甲素的作用.结果表明，Aβ_25-35可降低细胞活力，Triptolide 处理后分化的PC12细胞活力显著增加。结果表明雷公藤甲素可以减轻 Aβ_25-35引起的细胞损伤，说明雷公藤甲素具有神经保护作用^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

小鼠接受静脉注射后 Triptolide (TP) 血浆浓度迅速下降。注射 2 小时后，所有三组的 Triptolide 浓度均降至低于定量下限。在对照组和处理组之间进行参数比较，以评估 P-gp 抑制对 Triptolide 暴露和消除的影响。mdr1a-siRNA处理可显著增加雷公藤甲素血浆暴露，C_max从 413±74 增加到510±94 ng/mL (P<0.05)，AUC 从 103.5±9.6 增加到 154.3±30.2 ng h/mL (P<0.05)。在 Tariquidar 的伴随组中，还注意到显著增加的 AUC，从对照的 103.5±9.6 到 Triptolide + Tariquidar 组的 145.9±24.6 ng h/mL。因此，雷公藤甲素在小鼠体内的总体清除率显著降低，从对照组的 9564±1024.2 mL/min/kg 降至对照组的 6576.4±1438.5 (P<0.05) 和对照组的 5755.4±1200.1 mL/min/kg (P<0.05) 分别为雷公藤甲素+Tariquidar和雷公藤甲素+mdr1a-siRNA组^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

360.40

Formula

C₂₀H₂₄O₆

CAS 号

38748-32-2

性状

固体

颜色

White to off-white

中文名称

雷公藤甲素；雷藤素甲；雷公藤内酯醇；雷公藤多甙

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 25 mg/mL (69.37 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7747 mL	13.8735 mL	27.7469 mL
5 mM	0.5549 mL	2.7747 mL	5.5494 mL
10 mM	0.2775 mL	1.3873 mL	2.7747 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.17 mg/mL (3.25 mM); 澄清溶液

此方案可获得 ≥ 1.17 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 11.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 1.17 mg/mL (3.25 mM); 澄清溶液

此方案可获得 ≥ 1.17 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 11.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.86%

选择批次：

Data Sheet (671 KB) SDS (393 KB)

COA (177 KB) HNMR (267 KB) LCMS (261 KB) OR (171 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Ganguly S, et al. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget. 2015 Oct 13;6(31):31767-79. [Content Brief]

[2]. Huang M, et al. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther. 2013 Feb;12(2):184-94. [Content Brief]

[3]. Xu P, et al. Triptolide Inhibited Cytotoxicity of Differentiated PC12 Cells Induced by Amyloid-Beta25-35 via the Autophagy Pathway. PLoS One. 2015 Nov 10;10(11):e0142719. [Content Brief]

[4]. Kong LL, et al. Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. Sci Rep. 2015 Jul 2;5:11747. [Content Brief]

[5]. Zhang W, et al. Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism. Int J Mol Sci. 2016 Dec 19;17(12). pii: E2139. [Content Brief]

[6]. Cai J, et al. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. J Exp Clin Cancer Res. 2021;40(1):190. Published 2021 Jun 9. [Content Brief]

Cell Assay ^[3]	The viability of differentiated PC12 cells treated with different concentrations of Triptolide. After differentiated PC12 cells are cultured on 96-well plates with RPMI 1640 medium for stabilization, differentiated PC12 cells are incubated with different concentrations of Triptolide (0.01, 0.1, and 1 nM) for 24 hours. The concentrations in this study are chosen. Then cell viability is determined by the MTT assay. Each condition and experiment is repeated three times^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[4]	Mice^[4] Male BALB/C mice (weight, 18-22 g) are used. For Triptolide (TP) plasma kinetic study and toxicological evaluation, mice are divided into four groups (n=5 each) to collect blood and tissue samples: (1) normal+saline group; (2) 1.0 mg/kg Triptolide+15 nmol negative control (NC) siRNA-siRNA group; (3) 1.0 mg/kg Triptolide+15 nmol mdr1a-siRNA group; (4) 1.0 mg/kg Triptolide+10 mg/kg Tariquidar group. In order to avoid the complication caused by drug absorption or possible intestinal first-pass effect, Triptolide and the inhibitor are intravenously administrated to mice. The siRNA group is intravenously injected with NC-siRNA or mdr1a-siRNA 2 days before Triptolide dose. For Triptolide+Tariquidar group, the mice are received an intravenous Tariquidar dose 20 min prior to the Triptolide injection. Blood samples are collected at 2, 5, 10, 15, 30, 60 and 120 min after Triptolide dosing. To assess the liver exposure of Triptolide, liver tissue samples are collected from another set of mice at 5, 30, 60 and 120 min after dosing. Three Triptolide groups are design for this experiment, including Triptolide+NC-siRNA group, Triptolide+mdr1a-siRNA group and Triptolide+Tariquidar group. The liver tissue samples are weighed and then homogenized in 10 volume (w:v) of ice-cold saline. The concentrations of Triptolide in plasma and liver tissue are measured by a validated LC-MS/MS method. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Ganguly S, et al. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget. 2015 Oct 13;6(31):31767-79. [Content Brief] [2]. Huang M, et al. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther. 2013 Feb;12(2):184-94. [Content Brief] [3]. Xu P, et al. Triptolide Inhibited Cytotoxicity of Differentiated PC12 Cells Induced by Amyloid-Beta25-35 via the Autophagy Pathway. PLoS One. 2015 Nov 10;10(11):e0142719. [Content Brief] [4]. Kong LL, et al. Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. Sci Rep. 2015 Jul 2;5:11747. [Content Brief] [5]. Zhang W, et al. Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism. Int J Mol Sci. 2016 Dec 19;17(12). pii: E2139. [Content Brief] [6]. Cai J, et al. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. J Exp Clin Cancer Res. 2021;40(1):190. Published 2021 Jun 9. [Content Brief]

Triptolide 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7747 mL	13.8735 mL	27.7469 mL	69.3674 mL
	5 mM	0.5549 mL	2.7747 mL	5.5494 mL	13.8735 mL
	10 mM	0.2775 mL	1.3873 mL	2.7747 mL	6.9367 mL
	15 mM	0.1850 mL	0.9249 mL	1.8498 mL	4.6245 mL
	20 mM	0.1387 mL	0.6937 mL	1.3873 mL	3.4684 mL
	25 mM	0.1110 mL	0.5549 mL	1.1099 mL	2.7747 mL
	30 mM	0.0925 mL	0.4624 mL	0.9249 mL	2.3122 mL
	40 mM	0.0694 mL	0.3468 mL	0.6937 mL	1.7342 mL
	50 mM	0.0555 mL	0.2775 mL	0.5549 mL	1.3873 mL
	60 mM	0.0462 mL	0.2312 mL	0.4624 mL	1.1561 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Triptolide38748-32-2PG490雷公藤甲素雷藤素甲雷公藤内酯醇雷公藤多甙PG 490PG-490NF-κBApoptosisNuclear factor-κBNuclear factor-kappaBInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Triptolide (Synonyms: 雷公藤甲素; PG490)

Customer Review

Other Forms of Triptolide:

MCE 顾客使用本产品发表的 43 篇科研文献

Triptolide 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 NF-κB 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Triptolide 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Triptolide (Synonyms: 雷公藤甲素; PG490)

Customer Review

Other Forms of Triptolide:

Triptolide 相关抗体

MCE 顾客使用本产品发表的 43 篇科研文献

Triptolide 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 NF-κB 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Triptolide 相关抗体:

摩尔计算器

稀释计算器

Triptolide 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z